BYSI (BeyondSpring Inc) Company Cash on Hand

Graphic logo of beyondspringpharma.com (BYSI)

BeyondSpring Inc. (BYSI) generates revenue through the promotion of Plinabulin for the treatment of lung cancer and neutropenia. The cash flow trend on the GURU.Markets chart, where 0.00 represents the current metric level, confirms a dependency on procurement by clinics and insurance funds. However, an acute need for capital to fund new trials and previous FDA rejections create significant risks.

BYSI - BeyondSpring, Inc. Company Cash Balance over the range 07/04/2022 - 11/20/2026

Financial and market metric breakdowns for BeyondSpring (BYSI)

- current price and projected stock value:
Comprehensive company analysis:BYSI BeyondSpring Pharma
Signature product of beyondspringpharma.com

BeyondSpring Inc. is currently focusing on strengthening its position within the oncology sector amid a pragmatic approach from investors. The liquid assets metric quantifies the capital available for operations, allowing the cash reserve trend to determine either a fundamental floor or the risk of resource stagnation, where excess cash loses value without effective reinvestment into business development.